Association of hypernatremia with mortality in patients with COVID-19: a
systematic review and meta-analysis
Abstract
Abstract Background: The purpose of this meta-analysis was to look at
the relationship between hypernatremia and mortality in COVID-19
patients. Methods: We searched the PubMed, Web of science, Embase and
Cochrane databases for articles published from the inception of the
database until August 27, 2022. Three researchers reviewed the
literature, retrieved data, and assessed the quality of the literature,
respectively. A meta-analysis was performed using State 17 software to
assess the value of the effect of hypernatremia on mortality in patients
with new coronavirus pneumonia. Results: A total of 9 publications was
finally included in this study, including a total of 11,801 patients
with COVID-19, including 1,278 in the hypernatremia group and 10,523 in
the normonatremia group. Meta-analysis showed that hypernatremia was
associated with mortality in patients with COVID-19 [OR = 4.15, 95%
CI (2.95-5.84), P = 0.002, I² = 66.7%] with a sensitivity of 0.36
[0.26, 0.48] and a specificity of 0.88 [ 0.83, 0.91]. The
posterior probability of mortality was 42% in patients with COVID-19
hypernatremia and 15% in patients who did not have COVID-19
hypernatremia. Conclusion: According to available data, hypernatremia is
associated with death in patients with COVID-19.